Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Adma Biologics (ADMA) saw its stock fall by 1.24% in the latest trading session, underperforming the broader market. The company is anticipated to announce earnings of $0.19 per share and revenue of $139.8 million in its upcoming report, reflecting significant year-over-year growth. Analysts' revisions to forecasts and the company's current Zacks Rank of #3 (Hold) and attractive Forward P/E ratio are key factors for investors to monitor.
ADMA Biologics, Inc. (ADMA) Stock Price, News, Quote & History
This Yahoo Finance page provides a detailed overview of ADMA Biologics, Inc. (ADMA) stock. It includes real-time stock price data, pre-market and after-hours trading information, key financial metrics, and charting tools. The page also offers various financial data points like market capitalization, price ranges, and links to recent news and company insights.
(ADMA) Price Dynamics and Execution-Aware Positioning
This article analyzes Adma Biologics Inc (NASDAQ: ADMA) price dynamics, highlighting a near-term positive sentiment that may shift and a broader weak alignment. It identifies an exceptional risk-reward short setup with a 26.5% downside target and outlines three AI-generated institutional trading strategies for different risk profiles. The analysis also provides multi-timeframe signal insights, including support and resistance levels for near-term, mid-term, and long-term horizons.
ADMA Biologics Inc - Common Stock (Nasdaq:ADMA) Price Chart
This page displays the current stock price and basic market data for ADMA Biologics Inc (Nasdaq: ADMA). It shows the real-time stock quote, percentage change, and the time of the last update. The article provides a quick overview of the company's stock performance.
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Adma Biologics (ADMA) experienced a significant drop in its stock price, falling 1.01% at the latest close, underperforming major market indices like the S&P 500, Dow, and Nasdaq. The company is projected to report strong earnings and revenue growth for its upcoming release and the full fiscal year, with positive analyst estimate revisions suggesting a favorable business outlook. Despite a Zacks Rank of #3 (Hold), its Forward P/E ratio indicates a discount compared to its industry average within the Medical - Biomedical and Genetics sector.
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) shares have dropped 4.8% since its last earnings report, underperforming the S&P 500, but the company's Q2 2026 earnings matched estimates, with revenues missing slightly due to Bivigam weakness despite strong Asceniv growth. The company reiterated its full-year 2026 guidance and continued share repurchases, while advancing its SG-001 hyperimmune globulin program.
Trading Systems Reacting to (ADMA) Volatility
This article from Stock Traders Daily discusses the volatility of Adma Biologics Inc (NASDAQ: ADMA), highlighting a mid-channel oscillation pattern and a significant risk-reward short setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis, indicating neutral to weak sentiment across different horizons. The piece emphasizes the platform's AI models for optimizing position sizing and managing risk for investors.
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP has announced an investigation into potential breaches of fiduciary duty by certain directors and officers of ADMA Biologics, Inc. (NASDAQ: ADMA). The firm is seeking to determine if the Company's leadership upheld its obligations to shareholders, especially those who purchased shares before August 9, 2024. Shareholders are encouraged to contact Bernstein Liebhard LLP to discuss their legal rights.
ADMA Biologics (ADMA) After Strong Q2 Results And Reaffirmed Guidance Is It A Bargain
ADMA Biologics (ADMA) reported strong Q2 2026 results with $124.4 million in sales and $37.82 million in net income, reaffirming full-year revenue guidance. Despite a year-to-date share price drop, the stock has seen positive short-term returns and a significant 5-year total shareholder return. Analysts believe the company is 46% undervalued with a fair value of $17.60, contingent on successful execution and avoiding setbacks.
Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty
Bernstein Liebhard LLP is investigating whether ADMA Biologics' directors and officers breached their fiduciary duties to shareholders, potentially leading to legal action. This probe follows another investigation by Berger Montague PC into alleged revenue inflation through channel-stuffing practices. Shareholders who purchased ADMA shares before August 9, 2024, are encouraged to contact the firm.
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP has launched an investigation into potential breaches of fiduciary duty by directors and officers of ADMA Biologics, Inc. (NASDAQ: ADMA). The firm is seeking to determine if the company's leadership has fulfilled its obligations to shareholders and whether legal remedies are available. Current ADMA shareholders, particularly those who purchased shares before August 9, 2024, are encouraged to contact Bernstein Liebhard for a confidential consultation.
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA
Bank of America Corp DE significantly increased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 107.5% in the first quarter, now owning 3.998 million shares valued at $36 million. Other institutional investors like Sachem Head, Westfield Capital, and Capital Research also raised their holdings, contributing to the high institutional ownership of 75.68%. While analyst sentiment is mixed with a "Hold" rating and a consensus price target of $18.67, ADMA Biologics matched its quarterly EPS estimates and reported a 2% year-over-year revenue increase.
Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum
ADMA Biologics reaffirmed its full-year 2026 revenue guidance of US$530 million to US$560 million after reporting solid Q2 2026 results. The company's performance, including higher quarterly and year-to-date EPS, indicates management confidence despite a previous, more bullish guidance reset. The article highlights the importance of production scaling, yield efficiency, and plasma availability to ADMA's investment narrative, which projects significant revenue and earnings growth by 2029.
ADMA|ADMA Biologics Inc|Price:9.410|Chg%:-0.370
This article provides a detailed overview of ADMA Biologics Inc. (ADMA) stock, including its current price, market performance, key financial figures, and analyst ratings. It also offers technical analysis, company profile, ownership breakdown, and related instruments in the pharmaceutical sector.
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) alleging investor harm due to false and misleading statements made by the company. The lawsuit claims ADMA engaged in an undisclosed related-party transaction, used channel stuffing, and lacked adequate internal controls. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, are encouraged to join the case and may have until August 10, 2026, to request lead plaintiff status.
Janus Henderson Group PLC Trims Stock Holdings in ADMA Biologics Inc $ADMA
Janus Henderson Group PLC significantly reduced its stake in ADMA Biologics Inc by 97.5% in the first quarter, selling over 3.8 million shares and retaining 98,261 shares. Despite this, institutional investors still hold 75.68% of ADMA. The company reported in-line EPS but slightly missed revenue estimates, and is currently facing securities-related lawsuits which could impact investor confidence.
Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA
Royal Bank of Canada significantly increased its stake in ADMA Biologics Inc. by 448.8% in the first quarter, purchasing 759,984 additional shares, bringing its total to 929,326 shares valued at approximately $8.37 million. ADMA Biologics recently reported quarterly EPS of $0.16, meeting expectations, though revenue of $124.39 million slightly missed estimates. The company faces mixed analyst sentiment, an average "Hold" rating, and is currently involved in a pending securities lawsuit regarding alleged financial misrepresentations.
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP ("SBS") has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged securities fraud, reminding investors who purchased shares during the class period (August 9, 2024, to March 25, 2026) to contact the firm regarding lead plaintiff appointments. The complaint alleges that ADMA made false and misleading statements, failed to disclose a related party transaction, used channel stuffing to inflate revenue, and lacked appropriate internal controls, causing investor damages. The deadline to participate is August 10, 2026.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP has reminded investors of the August 10, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit against ADMA Biologics, Inc. The lawsuit alleges that ADMA Biologics made false and misleading statements, including engaging in an undisclosed related-party transaction, using channel stuffing to inflate revenue, and lacking adequate internal controls. These alleged actions led to a significant drop in ADMA Biologics' stock price after a report by Culper Research exposed the practices.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) alleging misrepresentations regarding the company's financial condition, revenue recognition, inventory distribution, and business practices. The lawsuit claims that the company engaged in undisclosed related-party transactions and "channel stuffing," leading to significant stock price drops following corrective disclosures. Investors who suffered substantial losses are encouraged to contact Hagens Berman by the August 10, 2026 application deadline.
ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors
Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA), alleging misrepresentations concerning the company's financial condition, revenue recognition, inventory distribution, and business practices. Investors who suffered substantial losses during the period of August 9, 2024, to March 25, 2026, have an opportunity to lead the class action, with a lead plaintiff deadline of August 10, 2026. The lawsuit claims that the company engaged in undisclosed related-party transactions, used channel stuffing, and lacked adequate internal controls, leading to significant stock value declines following corrective disclosures.
DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026
Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors. The lawsuit alleges misrepresentations regarding the company's financial condition, revenue recognition, inventory distribution, and business practices, including an undisclosed related party transaction and channel stuffing. Investors who suffered losses are advised to contact Hagens Berman before the August 10, 2026, lead plaintiff deadline.
ADMA BIOLOGICS CLASS ACTION DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. Stockholders to Contact the Firm Regarding Their Rights Before August 10th
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA made false statements and failed to disclose that it engaged in an undisclosed related party transaction and used channel stuffing to inflate revenue. Investors have until August 10, 2026, to apply to be lead plaintiff.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against ADMA Biologics, Inc. for alleged federal securities law violations. The lawsuit seeks to recover losses for investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, claiming the company failed to disclose material information and engaged in fraudulent practices. Investors have until August 10, 2026, to apply for lead plaintiff status.
First Trust Advisors LP Raises Stock Holdings in ADMA Biologics Inc $ADMA
First Trust Advisors LP significantly increased its stake in ADMA Biologics Inc. by 1,361.1% in the first quarter, now owning 360,217 shares. Despite this increased institutional ownership and strong quarterly performance in some areas, the company faces risks including revenue slightly missing estimates due to BIVIGAM weakness and ongoing securities-fraud litigation allegations. Analysts have varied ratings, with a consensus "Hold" and an average price target of $18.67.
ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
Kahn Swick & Foti, LLC (KSF) is reminding investors of ADMA Biologics, Inc. (ADMA) with losses over $100,000 that the deadline to file lead plaintiff applications in a securities class action lawsuit is August 10, 2026. The lawsuit alleges that ADMA and its executives failed to disclose material information, including an undisclosed related party transaction, channel stuffing, and inadequate internal controls, leading to investor damages. KSF encourages affected investors to contact them to discuss their legal rights.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged federal securities law violations between August 9, 2024, and March 25, 2026. Investors are accused of suffering losses due to undisclosed related-party transactions, channel stuffing, and inadequate internal controls. The deadline for investors to apply to be lead plaintiff in the lawsuit, Mazzarino v. ADMA Biologics, Inc., et al, is August 10, 2026.
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors
Robbins Geller Rudman & Dowd LLP reminds investors of ADMA Biologics, Inc. who purchased securities between August 9, 2024, and March 25, 2026, that they have until Monday, August 10, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that ADMA Biologics made false or misleading statements regarding undisclosed related-party transactions, channel stuffing, and inadequate internal controls, leading to significant stock declines following reports from Culper Research and a subsequent downgrade by Cantor Fitzgerald. Investors who suffered substantial losses are encouraged to contact the firm for more information.
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) alleging misrepresentations regarding the company's financial condition, revenue recognition, inventory distribution, and business practices. The lawsuit claims that the company engaged in an undisclosed related-party transaction and used channel stuffing to inflate revenue, leading to substantial shareholder losses after corrective disclosures, including a short-seller report. Investors with losses during the August 9, 2024 – March 25, 2026 class period are encouraged to come forward to lead the lawsuit.
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
ADMA Biologics (ADMA) reported Q2 2026 earnings that matched analyst estimates at 16 cents per share, but revenues of $124.4 million missed expectations due to a significant decline in Bivigam sales. The company's Asceniv product, however, showed strong growth, helping to drive an expansion in gross margin. ADMA reiterated its 2026 financial guidance and continues to invest in its pipeline and share repurchase program.
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders
Glancy Prongay Wolke & Rotter LLP is reminding investors of ADMA Biologics, Inc. (ADMA) about an upcoming August 10, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges securities fraud, claiming ADMA engaged in channel stuffing, an undisclosed related party transaction, and lacked adequate internal controls, leading to misleading positive statements about the company's prospects. These allegations arose after a report from Culper Research caused ADMA's stock price to fall significantly.
ADMA Biologics (Nasdaq: ADMA) grows Q2 profit and ASCENIV sales
ADMA Biologics reported significantly higher profitability in Q2 2026, driven by strong ASCENIV sales, despite modest overall revenue growth. The company announced a 24% increase in ASCENIV revenue, contributing to a 69% gross margin and an 11% rise in GAAP net income. ADMA reiterated its full-year 2026 financial guidance and highlighted positive real-world data for ASCENIV.
Earnings Flash (ADMA) ADMA Biologics, Inc. Reports Q2 Revenue $124.4M, vs. FactSet Est of $125.3M
ADMA Biologics, Inc. reported its Q2 revenue at $124.4 million, which was slightly below the FactSet estimate of $125.3 million. The company, a biopharmaceutical firm specializing in plasma-derived biologics, is scheduled to hold its Q2 2026 Earnings Call on August 5, 2026. This earnings flash provides a quick overview of their financial performance for the second quarter.
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
ADMA Biologics reported strong second-quarter 2026 financial results, with total revenue reaching $124.4 million, up 2% year-over-year, driven primarily by ASCENIV sales which grew 24% to $102.9 million. The company reiterated its full-year 2026 financial guidance and highlighted new real-world data supporting ASCENIV's effectiveness in treating primary immunodeficiency patients. ADMA also continued its share repurchase program and advanced its SG-001 development pipeline.
ADMA Biologics earnings up next: Can plasma maker rebound? By Investing.com
ADMA Biologics is set to report second-quarter earnings, with investors focused on whether the company can rebound from a disappointing prior quarter. Despite recent declines in analyst estimates, Wall Street remains optimistic with a mean price target of $17, implying significant upside. Key factors to watch include sequential revenue acceleration, margin sustainability, and the commercial impact of recent FDA approval for ASCENIV.
ADMA Biologics, Inc. Notice of August 10, 2026 Application
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against ADMA Biologics, Inc. (ADMA), notifying investors of a deadline to apply as lead plaintiff by August 10, 2026. The lawsuit alleges that ADMA and its executives failed to disclose material information and violated federal securities laws, including engaging in an undisclosed related party transaction, using channel stuffing, and lacking adequate internal controls, which led to investor damages. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, are encouraged to contact KSF for more information.
ADMA DEADLINE: The Gross Law Firm Reminds ADMA Biologics, Inc. Investors of Upcoming Securities Class Action Deadline
The Gross Law Firm is reminding investors of ADMA Biologics, Inc. (NASDAQ: ADMA) about an upcoming securities class action deadline of August 10, 2026. The lawsuit alleges that ADMA Biologics issued materially false and/or misleading statements, including engaging in an undisclosed related party transaction, using channel stuffing to inflate revenue, and lacking adequate internal controls, during the class period from August 9, 2024, to March 25, 2026. Shareholders who purchased shares during this period are encouraged to contact the firm to potentially be appointed as lead plaintiff.
Portnoy Law Firm Announces Class Action on Behalf of ADMA Biologics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026. The lawsuit alleges that ADMA Biologics and its executives made false and misleading statements by failing to disclose a related party transaction, using channel stuffing to inflate revenue appearance, and lacking adequate internal controls. Investors have until August 10, 2026, to file a lead plaintiff motion.
ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Hagens Berman has filed a securities fraud class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA), alleging that the company made misrepresentations regarding its financial condition, revenue recognition, inventory distribution, and business practices. The lawsuit claims that the company engaged in undisclosed related-party transactions and used "channel stuffing" to inflate revenue, leading to substantial shareholder losses after corrective disclosures, including a short-seller report. Investors with significant losses during the class period of August 9, 2024, to March 25, 2026, are encouraged to contact Hagens Berman to potentially lead the lawsuit.
ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors
A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. and its executives following a 29% stock drop. The lawsuit alleges that ADMA engaged in a channel stuffing scheme to inflate revenue growth, purportedly driven by claims from Culper Research. Investors have until August 10, 2026, to seek lead plaintiff status in the case.
ADMA Biologics Inc (ADMA) Stock Analysis: A Look At Its 100.95% Potential Upside
ADMA Biologics Inc (NASDAQ: ADMA) is highlighted as a compelling investment in the biotechnology sector, specializing in plasma-derived biologics for immune deficiencies. Analysts are bullish, projecting a potential upside of 100.95% from its current trading price, with an average target price of $17.00. The company shows strong financials with a forward P/E of 8.59, 15.90% revenue growth, and an exceptional 43.30% return on equity, despite not offering a dividend.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologic
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ADMA Biologics, Inc. following a short report from Culper Research. The report alleges that ADMA's reported growth is artificial, driven by a "channel stuffing scheme and an undisclosed related party distributor," leading to a significant drop in ADMA's stock price. The law firm is encouraging investors who purchased ADMA securities to come forward and assist in their investigation.
ADMA BIOLOGICS CLASS ACTION DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. Stockholders to Contact the Firm Regarding Their Rights Before August 10th
Bragar Eagel & Squire, P.C. is reminding ADMA Biologics, Inc. stockholders that the deadline to apply to be lead plaintiff in a class action lawsuit is August 10, 2026. The lawsuit alleges that ADMA made false or misleading statements regarding its business, including an undisclosed related party transaction and using channel stuffing to inflate revenue. Investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, and suffered losses are encouraged to contact the law firm.
ADMA Biologics Inc expected to post earnings of 17 cents a share - Earnings Preview
ADMA Biologics Inc is expected to report earnings of 17 cents per share. This information comes from a Refinitiv earnings preview. The full article is available to TradingView subscribers.
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against ADMA Biologics, Inc. for alleged violations of federal securities laws. The lawsuit claims ADMA failed to disclose a related party transaction, used channel stuffing to inflate revenue, and lacked adequate internal controls, misleading investors who purchased securities between August 9, 2024, and March 25, 2026. Investors have until August 10, 2026, to apply to be appointed as lead plaintiff.
ADMA INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the August 10, 2026 Lead Plaintiff Deadline ADMA Biologics, Inc. Securities Class Action
Holzer & Holzer, LLC has filed a shareholder class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA), alleging the company made false and misleading statements, including an undisclosed related party transaction, channel stuffing, and inadequate internal controls. Investors who purchased ADMA shares between August 9, 2024, and March 25, 2026, and experienced losses are encouraged to contact the firm, with an August 10, 2026, deadline to apply for lead plaintiff status.
ADMA BIOLOGICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL,
Rosen Law Firm is reminding investors of ADMA Biologics, Inc. (NASDAQ: ADMA) who incurred losses exceeding $100K during the Class Period (August 9, 2024, to March 25, 2026) to secure legal counsel. The deadline to move for lead plaintiff in the securities class action is August 10, 2026. The lawsuit alleges that ADMA Biologics made materially false or misleading statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls.
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against ADMA Biologics, Inc. (ADMA) for alleged securities fraud. The lawsuit claims ADMA made false and misleading statements, including undisclosed related-party transactions and "channel stuffing" to inflate revenue. Investors who purchased ADMA shares between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff appointment.
ADMA Class Action Notice: ADMA Biologics Hit with Securities Fraud Lawsuit over Channel Stuffing Misrepresentations – Investors Urged to Contact BFA Law by August 10 Deadline
ADMA Biologics is facing a securities fraud class action lawsuit due to allegations of a "channel stuffing" scheme that misrepresented its 2025 revenue growth. The lawsuit follows a report by Culper Research, which claimed ADMA artificially inflated its reported 20% growth by inducing a distributor to stock excess product. Investors have until August 10, 2026, to contact Bleichmar Fonti & Auld LLP to lead the case against the company.
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BitGo Holdings, Inc. (BTGO), ADMA Biologics, Inc. (ADMA), and Via Transportation, Inc. (VIA) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against BitGo Holdings, Inc. (BTGO), ADMA Biologics, Inc. (ADMA), and Via Transportation, Inc. (VIA). Investors who suffered losses in these companies are encouraged to contact the firm to discuss their legal rights. The deadlines to seek appointment as lead plaintiff are August 7, 2026 for BitGo and August 10, 2026 for ADMA and Via Transportation.
